SpliSense

SpliSense is a dynamic biotechnology company dedicated to pioneering innovative therapies for genetic diseases, with a focus on inhalation-based treatments. SpliSense is committed to improving patient outcomes through advanced research and development in the biotechnology sector.

Located at The Hebrew University of Jerusalem Silberman Building 78, Jerusalem, 9190401, IL, SpliSense is currently channeling its expertise into addressing splicing mutations within the CFTR gene, aiming to provide effective solutions for Cystic Fibrosis (CF) patients. This focus underscores SpliSense's dedication to tackling critical healthcare challenges through cutting-edge biotechnological advancements.

Founded in 2017, SpliSense operates as a privately held entity and is rapidly growing, driven by a mission to deliver transformative treatments. With a strong foundation in biotechnology research, SpliSense is poised to make significant contributions to the field of genetic disease therapy. We invite the management team at SpliSense to enrich our platform with a customized company showcase and product listings.